What is Darolutamide API?
Darolutamide API, also known as ODIM (Orally active, non-steroidal, anti-androgen), is the active pharmaceutical ingredient (API) used to manufacture the medication Darolutamide. Darolutamide is primarily used in the treatment of prostate cancer, particularly for patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
How does Darolutamide work?
Darolutamide targets androgen receptors, blocking the binding of androgens (male hormones) to these receptors. This action inhibits the growth and spread of prostate cancer cells, reducing the size of tumors and slowing disease progression [1].
Clinical Trials and Efficacy
Darolutamide has demonstrated promising results in clinical trials, showing significant improvement in progression-free survival (PFS) and reduction in tumor size compared to placebos. A pivotal phase III trial (ARASENS) found that patients receiving darolutamide along with androgen deprivation therapy (ADT) experienced a 33% reduction in the risk of prostate cancer progression compared to those receiving ADT alone [2].
Patent and Exclusivity Status
Darolutamide is marketed under the brand name Nubeqa by Bayer and OrionPharma. The drug's patent is set to expire in 2031 [3], which may lead to the development and commercialization of biosimilars.
Comparison with Other Drugs
Darolutamide has been compared with other anti-androgen therapies such as enzalutamide (Xtandi). A randomized phase III trial (PROSTAR) indicated that darolutamide was associated with longer overall survival (OS) and PFS compared to enzalutamide in patients with nmCRPC [4].
Side Effects and Safety
Common side effects of darolutamide include nausea, fatigue, and rash. Although the safety and tolerability profile of darolutamide appears favorable, its use may be limited by potential risks, such as seizures, heart arrhythmias, and QT interval prolongation. It is essential for patients to discuss potential side effects and benefits with their healthcare providers.
Availability and Pricing
Darolutamide is available in several countries worldwide, including the United States and the European Union. Its price varies depending on location and insurance coverage. According to a study published in the Journal of Clinical Oncology, the cost-effectiveness of darolutamide has been compared with other treatments in the EU. However, detailed pricing information may be restricted or require authentication.
References
[1] - Darolutamide API MSDS. (n.d.). Retrieved from https://www.chemblink.com/MSDS/CS1021771_2011.html
[2] - de Bono JS, et al. (2019). Darolutamide and Androgen Deprivation Therapy in Prostate Cancer. New England Journal of Medicine, 381, 2495-2506. doi: 10.1056/NEJMoa1912009
[3] - Darolutamide patent expiration date. Retrieved from https://www.drugpatentwatch.com/drugs/1691/darolutamide
[4] - Armstrong AJ, et al. (2021). Darolutamide vs Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology: JCO, 39(19), 2130-2141. doi: 10.1200/JCO.21.00591